| abstract |
This invention comprises an extract of Artemisia dracunculus that can be used for the treatment and prevention of diabetes, diabetic complications, metabolic syndrome and other comorbidities that share the underlying commonality of insulin resistance. The invention includes the identity of six compounds from the extract that contribute to the activity of the extract by inhibiting protein tyrosine phosphatase- 1B (PTP-1B) activity, phosphoenolpyruvate carboxykinase (PEPCK) gene expression or aldose reductase activity (ALR2). The compounds include 4, 5-Di-O- caffeoylquinic acid, davidigenin, 6-demethoxycapilIarisin, 2',4-dihydroxy-4'- methoxydihydrochalcone, 2',4'-dihydroxy-4-.rnethoxydihydrochalcone and sakuranetin. |